Liposome: Classification, Preparation, and Applications

Overview

Journal Nanoscale Res Lett

Publisher Springer

Specialty Biotechnology

Date 2013 Feb 26

PMID 23432972

Citations 851

Authors

Abolfazl Akbarzadeh

Rogaie Rezaei-Sadabady

Soodabeh Davaran

Sang Woo Joo

Nosratollah Zarghami

Younes Hanifehpour

Mohammad Samiei

Mohammad Kouhi

Kazem Nejati-Koshki

Affiliations

Soon will be listed here.

Abstract

Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were first described in the mid-60s. Today, they are a very useful reproduction, reagent, and tool in various scientific disciplines, including mathematics and theoretical physics, biophysics, chemistry, colloid science, biochemistry, and biology. Since then, liposomes have made their way to the market. Among several talented new drug delivery systems, liposomes characterize an advanced technology to deliver active molecules to the site of action, and at present, several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to 'second-generation liposomes', in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. This paper summarizes exclusively scalable techniques and focuses on strengths, respectively, limitations in respect to industrial applicability and regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.

Citing Articles

Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.

Maksymova L, Pilger Y, Nuhn L, Van Ginderachter J Mol Cancer. 2025; 24(1):65.

PMID: 40033293 PMC: 11877942. DOI: 10.1186/s12943-025-02270-5.

Development, Characterization, and Antimicrobial Evaluation of Hybrid Nanoparticles (HNPs) Based on Phospholipids, Cholesterol, Colistin, and Chitosan Against Multidrug-Resistant Gram-Negative Bacteria.

Perdomo I, Mora C, Pinillos J, Onate-Garzon J, Salamanca C Pharmaceutics. 2025; 17(2).

PMID: 40006549 PMC: 11859251. DOI: 10.3390/pharmaceutics17020182.

Nanoparticle-Encapsulated Plant Polyphenols and Flavonoids as an Enhanced Delivery System for Anti-Acne Therapy.

Puspadewi R, Milanda T, Muhaimin M, Chaerunisaa A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006023 PMC: 11858878. DOI: 10.3390/ph18020209.

The Effect of Nanoparticles as an Endodontic Irrigant on the Morphology, Viability, Migration, and Proliferation of Human Bone Marrow Mesenchymal Stem Cells: An In Vitro Study.

AlMobarak S, AlMadi E, Almohaimede A, Badran M, Lambarte R Int J Mol Sci. 2025; 26(4).

PMID: 40003879 PMC: 11855132. DOI: 10.3390/ijms26041412.

Deep-insights: Nanoengineered gel-based localized drug delivery for arthritis management.

Sriram A, Ithape H, Singh P Asian J Pharm Sci. 2025; 20(1):101012.

PMID: 39995751 PMC: 11848107. DOI: 10.1016/j.ajps.2024.101012.

References

Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan M, Keating M . Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985; 151(4):704-10. DOI: 10.1093/infdis/151.4.704. View

Daemen T, Hofstede G, ten Kate M, Scherphof G . Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer. 1995; 61(5):716-21. DOI: 10.1002/ijc.2910610520. View

Ohsawa T, Miura H, Harada K . Improvement of encapsulation efficiency of water-soluble drugs in liposomes formed by the freeze-thawing method. Chem Pharm Bull (Tokyo). 1985; 33(9):3945-52. DOI: 10.1248/cpb.33.3945. View

Eckardt J, Campbell E, Burris H, Weiss G, Rodriguez G, Fields S . A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol. 1994; 17(6):498-501. DOI: 10.1097/00000421-199412000-00009. View

Swenson C, Popescu M, GINSBERG R . Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol. 1988; 15 Suppl 1:S1-31. DOI: 10.3109/10408418809104463. View

New R, Chance M, Thomas S, Peters W . Antileishmanial activity of antimonials entrapped in liposomes. Nature. 1978; 272(5648):55-6. DOI: 10.1038/272055a0. View

Schiffelers R, Storm G . Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res. 2001; 18(6):780-7. DOI: 10.1023/a:1011080211226. View

Valizadeh A, Mikaeili H, Samiei M, Mussa Farkhani S, Zarghami N, Kouhi M . Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res Lett. 2012; 7(1):480. PMC: 3463453. DOI: 10.1186/1556-276X-7-480. View

Banerjee R, Tyagi P, Li S, Huang L . Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004; 112(4):693-700. DOI: 10.1002/ijc.20452. View

10.

Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S . Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine. 2012; 7:511-26. PMC: 3273983. DOI: 10.2147/IJN.S24326. View

11.

Romberg B, Hennink W, Storm G . Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2007; 25(1):55-71. PMC: 2190344. DOI: 10.1007/s11095-007-9348-7. View

12.

Deamer D, Bangham A . Large volume liposomes by an ether vaporization method. Biochim Biophys Acta. 1976; 443(3):629-34. DOI: 10.1016/0005-2736(76)90483-1. View

13.

Song H, Geng H, Ruan J, Wang K, Bao C, Wang J . Development of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res Lett. 2011; 6(1):354. PMC: 3211444. DOI: 10.1186/1556-276X-6-354. View

14.

Guaglianone P, Chan K, Hanisch R, Jeffers S, Sharma D, Muggia F . Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs. 1994; 12(2):103-10. DOI: 10.1007/BF00874439. View

15.

Gill P, Espina B, Muggia F, Cabriales S, Tulpule A, Esplin J . Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995; 13(4):996-1003. DOI: 10.1200/JCO.1995.13.4.996. View

16.

Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M . Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res. 2004; 14(1-2):87-109. DOI: 10.1081/lpr-120039794. View

17.

Pick U . Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. Arch Biochem Biophys. 1981; 212(1):186-94. DOI: 10.1016/0003-9861(81)90358-1. View

18.

Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E . A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine. 1999; 17(9-10):1223-38. DOI: 10.1016/s0264-410x(98)00346-6. View

19.

Kunisawa J, Masuda T, Katayama K, Yoshikawa T, Tsutsumi Y, Akashi M . Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release. 2005; 105(3):344-53. DOI: 10.1016/j.jconrel.2005.03.020. View

20.

Gabizon A . Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res. 2001; 7(2):223-5. View